Renal sympathetic denervation: A novel intervention for resistant hypertension, insulin resistance, and sleep apnea

Hypertension

Volumn 58, Issue 4, 2011, Pages 542-543

  Egan, Brent M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; GLUCOSE; INSULIN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; EXTRACELLULAR FLUID; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN RESPONSE; KIDNEY DENERVATION; KIDNEY SYMPATHETIC DENERVATION; MUSCLE BLOOD FLOW; NOTE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SLEEP APNEA SYNDROME; SYMPATHETIC NERVE; VEIN COMPLIANCE;

BLOOD GLUCOSE; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; SLEEP; SLEEP APNEA, OBSTRUCTIVE; SYMPATHECTOMY;

EID: 80053544500     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.179101     Document Type: Note

References (12)

1. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Ś liwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-565.
2. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-1909.
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
4. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients. with resistant hypertension: a pilot study. Circulation. 2011;123: 1940-1946.
5. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010; 298:R245-R253.
6. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drugresistant hypertension. Hypertension. 2010;56:1077-1082.
7. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24:532-537.
8. Koistinen HA, Zierath JR. Regulation of glucose transport in skeletal muscle. Ann Med. 2002;34:410-418. (Pubitemid 36026772)
9. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
10. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010:375; 906-915.
11. Mancia G. Prognostic value of long-term blood pressure variability: the evidence is growing. Hypertension. 2011;57:141-143.
12. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209-215.